The APOE genotype: Modification of therapeutic responses in Alzheimer's disease

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 114-120

  Hanson, Angela J ^a,b   Craft, Suzanne ^c   Banks, William A ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; APOE genotype; Treatments

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E; BAPINUEZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ALLELE; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; ETHNICITY; GENDER; GENE; GENOTYPE; HUMAN; IMMUNIZATION; KETOGENIC DIET; LIPID DIET; NONHUMAN; TREATMENT RESPONSE; ANIMAL; DRUG DESIGN; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY; RISK FACTOR;

ALLELES; ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; DRUG DESIGN; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; RISK FACTORS;

EID: 84919714337     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141020164222     Document Type: Article

References (73)

1. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9(2): 106-18.
2. Fan J, Donkin J, Wellington C. Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. Biofactors 2009; 35(3): 239-48.
3. Holtzman DM, Herz J, Bu G. Apolipoprotein e and apolipoprotein e receptors: normal biology and roles in Alzheimer disease. Cold Spring Harbor Perspectives Med 2012; 2(3): a006312.
4. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA: the Journal of the American Medical Association 1997; 278(16): 1349-56.
5. Mahley RW, Huang Y, Weisgraber KH. Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2007; 4(5): 537-40.
6. Caselli RJ. Phenotypic differences between apolipoprotein E genetic subgroups: research and clinical implications. Alzheimer's Res Therapy 2012; 4(3): 20.
7. Koffie RM, Hashimoto T, Tai HC, et al. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain: a J Neurol 2012; 135(Pt 7): 2155-68.
8. de Chaves EP, Narayanaswami V. Apolipoprotein E and cholesterol in aging and disease in the brain. Future Lipidol 2008; 3(5): 505-30.
9. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 2002; 924(1): 90-7.
10. Allen SJ, MacGowan SH, Tyler S, et al. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci letters 1997; 239(1): 33-6.
11. Patterson CE, Todd SA, Passmore AP. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogenom J 2011; 11(6): 444-50.
12. Dickstein DL, Walsh J, Brautigam H, Stockton SD, Jr., Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mount Sinai J Med, New York 2010; 77(1): 82-102.
13. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 2013; 340(6135): 924-c.
14. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and Reverse Deficits in AD Mouse Models. Science 2012.
15. Caselli RJ. Does an Alzheimer's disease susceptibility gene influence the cognitive effects of cancer therapy? Pediatric blood & cancer 2013.
16. Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA. The greater sensitivity of elderly APOE epsilon4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am J Geriatric Pharmacotherapy 2012; 10(3): 185-92.
17. Farlow MR. Should the ApoE genotype be a covariate for clinical trials in Alzheimer disease? Alzheimer's Res Therapy 2010; 2(3): 15.
18. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med 2014; 370(4): 322-33.
19. Roher AE, Maarouf CL, Daugs ID, et al. Neuropathology and amyloid-beta spectrum in a bapineuzumab immunotherapy recipient. J Alzheimer's disease: JAD 2011; 24(2): 315-25.
20. Zhang H, Wu LM, Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflammation 2011; 2011: 949072.
21. Zamani M, Mehri M, Kollaee A, et al. Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients. Dementia Geriatric Cognitive Disorders Extra 2011; 1(1): 180-9.
22. Jack CR, Jr., Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 2008; 29(9): 1285-95.
23. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Eng J Med 2005; 352(23): 2379-88.
24. Wang L, Day J, Roe CM, et al. The Effect of APOE epsilon4 Allele on Cholinesterase Inhibitors in Patients With Alzheimer Disease: Evaluation of the Feasibility of Resting State Functional Connectivity Magnetic Resonance Imaging. Alzheimer Disease Associated Disorders 2014; 28(2): 122-7.
25. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS drugs 2010; 24(2): 163-76.
26. Zhong Y, Zheng X, Miao Y, Wan L, Yan H, Wang B. Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease. Am J Med Sci 2013; 345(3): 222-6.
27. Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. Curr Med Res Opinion 2011; 27(7): 1375-83.
28. Wroolie TE, Kenna HA, Williams KE, et al. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. Acta Neurologica Scandinavica 2009; 119(3): 172-9.
29. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352(9137): 1347-51.
30. Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. J Alzheimer's disease: JAD 2010; 20(4): 1083-90.
31. Poon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008; 28(3): 366-75.
32. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Archives Internal Med 2009; 169(13): 1195-202.
33. Wyss JM, Kadish I, van Groen T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens 2003; 25(7): 455-74.
34. Qiu WQ, Mwamburi M, Besser LM, et al. Angiotensin Converting Enzyme Inhibitors and the Reduced Risk of Alzheimer's Disease in the Absence of Apolipoprotein E4 Allele. J Alzheimer's Disease: JAD 2013.
35. Zou K, Yamaguchi H, Akatsu H, et al. Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. The Journal of neuroscience: the official Journal of the Society for Neuroscience 2007; 27(32): 8628-35.
36. Qiu WW, Lai A, Mon T, et al. Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. Am J Geriatric Psychiatry: official Journal of the American Association for Geriatric Psychiatry 2014; 22(2): 177-85.
37. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of Internal Medicine 2002; 162(18): 2046-52.
38. Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an openlabel trial. Int J Geriatric Psychiatry 2012; 27(4): 415-22.
39. Henderson ST. High carbohydrate diets and Alzheimer's disease. Medical Hypotheses 2004; 62(5): 689-700.
40. Hanson AJ, Bayer-Carter JL, Green PS, et al. Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides: Randomized Clinical Trial. JAMA Neurol 2013: 1-9.
41. Huang TL, Zandi PP, Tucker KL, et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005; 65(9): 1409-14.
42. Barberger-Gateau P, Samieri C, Feart C, Plourde M. Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: interaction with apolipoprotein E genotype. Curr Alzheimer Res 2011; 8(5): 479-91.
43. Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cellular Mole Med 2008; 12(6B): 2762-71.
44. Rubin J, Berglund L. Apolipoprotein E and diets: a case of genenutrient interaction? Curr Opinion Lipidol 2002; 13(1): 25-32.
45. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebocontrolled, multicenter trial. Nutrition Metabol 2009; 6: 31.
46. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005; 64(9): 1531-8.
47. Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Safety 2013; 22(4): 345-58.
48. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatrics Soc 2010; 58(7): 1311-7.
49. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta neurologica Scandinavica Supplementum 2006; 185: 3-7.
50. Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochemical pharmacol 2014; 88(4): 605-16.
51. Samieri C, Lorrain S, Buaud B, et al. Relationship between diet and plasma long-chain n-3 PUFAs in older people: impact of apolipoprotein E genotype. J Lipid Res 2013; 54(9): 2559-67.
52. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA: the Journal of the American Medical Association 2010; 304(17): 1903-11.
53. Plourde M, Vohl MC, Vandal M, Couture P, Lemieux S, Cunnane SC. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br J Nutrition 2009; 102(8): 1121-4.
54. Chouinard-Watkins R, Rioux-Perreault C, Fortier M, et al. Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE epsilon4 allele. Br J Nutrition 2013; 110(10): 1751-9.
55. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Frontiers Aging Neurosci 2010; 2.
56. Drye LT, Zandi PP. Role of APOE and Age at Enrollment in the Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). Dementia Geriatric Cognitive Disorders Extra 2012; 2(1): 304-11.
57. Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabetic medicine: a Journal of the British Diabetic Association 2011; 28(12): 1463-75.
58. Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J clinical Investigation 2012.
59. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50(1): 164-8.
60. Dumurgier J, Paquet C, Peoc'h K, et al. CSF Abeta1-42 Levels and Glucose Metabolism in Alzheimer's Disease>. Journal of Alzheimer's disease: JAD 2011.
61. Despres JP, Verdon MF, Moorjani S, et al. Apolipoprotein E polymorphism modifies relation of hyperinsulinemia to hypertriglyceridemia. Diabetes 1993; 42(10): 1474-81.
62. Craft S, Asthana S, Schellenberg G, et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Annl New York Acad Sci 2000; 903: 222-8.
63. Risner ME, Saunders AM, Altman JF, et al. Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease. pharmacogenomics J 2006; 6(4): 246-54.
64. Reger MA, Watson GS, Green PS, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer's Disease: JAD 2008; 13(3): 323-31.
65. Claxton A, Baker LD, Wilkinson CW, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J Alzheimer's Disease: JAD 2013; 35(4): 789-97.
66. Altmann A, Tian L, Henderson VW, Greicius MD. Sex modifies the APOE-related risk of developing Alzheimer disease. Annl Neurol 2014; 75(4): 563-73.
67. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000; 54(10): 1949-54.
68. Jacobs EG, Kroenke C, Lin J, et al. Accelerated cell aging in female APOE-epsilon4 carriers: implications for hormone therapy use. PloS one 2013; 8(2): e54713.
69. Pendse AA, Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic syndrome, and beyond. J lipid Res 2009; 50 Suppl: S178-82.
70. To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S. The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PloS one 2011; 6(2): e16991.
71. Maloney B, Ge YW, Alley GM, Lahiri DK. Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease. J Neurochem 2007; 103(3): 1237-57.
72. Kennedy RE, Cutter GR, Schneider LS. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimer's & dementia: the Journal of the Alzheimer's Association 2014; 10(3): 349-59.
73. Wattmo C, Wallin AK, Minthon L. Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies. Alzheimer's Res Therapy 2013; 5(5): 44.